Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 62

1.

Vesicular nucleotide transporter mediates ATP release and migration in neutrophils.

Harada Y, Kato Y, Miyaji T, Omote H, Moriyama Y, Hiasa M.

J Biol Chem. 2018 Jan 23. pii: jbc.M117.810168. doi: 10.1074/jbc.M117.810168. [Epub ahead of print]

2.

Unique anti-myeloma activity by thiazolidine-2,4-dione compounds with Pim inhibiting activity.

Fujii S, Nakamura S, Oda A, Miki H, Tenshin H, Teramachi J, Hiasa M, Bat-Erdene A, Maeda Y, Oura M, Takahashi M, Iwasa M, Endo I, Yoshida S, Aihara KI, Kurahashi K, Harada T, Kagawa K, Nakao M, Sano S, Abe M.

Br J Haematol. 2018 Jan;180(2):246-258. doi: 10.1111/bjh.15033.

PMID:
29327347
3.

TAK1 inhibition subverts the osteoclastogenic action of TRAIL while potentiating its antimyeloma effects.

Tenshin H, Teramachi J, Oda A, Amachi R, Hiasa M, Bat-Erdene A, Watanabe K, Iwasa M, Harada T, Fujii S, Kagawa K, Sogabe K, Nakamura S, Miki H, Kurahashi K, Yoshida S, Aihara K, Endo I, Tanaka E, Matsumoto T, Abe M.

Blood Adv. 2017 Oct 26;1(24):2124-2137. doi: 10.1182/bloodadvances.2017008813. eCollection 2017 Nov 14.

4.

Skeletal anchorage for intrusion of bimaxillary molars in a patient with skeletal open bite and temporomandibular disorders.

Iwasa A, Horiuchi S, Kinouchi N, Izawa T, Hiasa M, Kawai N, Yasue A, Hassan AH, Tanaka E.

J Orthod Sci. 2017 Oct-Dec;6(4):152-158. doi: 10.4103/jos.JOS_63_17.

5.

Identification of a vesicular ATP release inhibitor for the treatment of neuropathic and inflammatory pain.

Kato Y, Hiasa M, Ichikawa R, Hasuzawa N, Kadowaki A, Iwatsuki K, Shima K, Endo Y, Kitahara Y, Inoue T, Nomura M, Omote H, Moriyama Y, Miyaji T.

Proc Natl Acad Sci U S A. 2017 Jul 18. pii: 201704847. doi: 10.1073/pnas.1704847114. [Epub ahead of print]

6.

Vesicular nucleotide transporter (VNUT): appearance of an actress on the stage of purinergic signaling.

Moriyama Y, Hiasa M, Sakamoto S, Omote H, Nomura M.

Purinergic Signal. 2017 Sep;13(3):387-404. doi: 10.1007/s11302-017-9568-1. Epub 2017 Jun 14. Review.

7.

Disruption of the Cx43/miR21 pathway leads to osteocyte apoptosis and increased osteoclastogenesis with aging.

Davis HM, Pacheco-Costa R, Atkinson EG, Brun LR, Gortazar AR, Harris J, Hiasa M, Bolarinwa SA, Yoneda T, Ivan M, Bruzzaniti A, Bellido T, Plotkin LI.

Aging Cell. 2017 Jun;16(3):551-563. doi: 10.1111/acel.12586. Epub 2017 Mar 19.

8.

Bone Pain Induced by Multiple Myeloma Is Reduced by Targeting V-ATPase and ASIC3.

Hiasa M, Okui T, Allette YM, Ripsch MS, Sun-Wada GH, Wakabayashi H, Roodman GD, White FA, Yoneda T.

Cancer Res. 2017 Mar 15;77(6):1283-1295. doi: 10.1158/0008-5472.CAN-15-3545. Epub 2017 Mar 2.

9.

Function and expression of a splicing variant of vesicular glutamate transporter 1.

Moriyama S, Iharada M, Omote H, Moriyama Y, Hiasa M.

Biochim Biophys Acta. 2017 May;1859(5):931-940. doi: 10.1016/j.bbamem.2017.02.002. Epub 2017 Feb 8.

PMID:
28188742
10.

Vesicular Polyamine Transporter Mediates Vesicular Storage and Release of Polyamine from Mast Cells.

Takeuchi T, Harada Y, Moriyama S, Furuta K, Tanaka S, Miyaji T, Omote H, Moriyama Y, Hiasa M.

J Biol Chem. 2017 Mar 3;292(9):3909-3918. doi: 10.1074/jbc.M116.756197. Epub 2017 Jan 12.

PMID:
28082679
11.

Pim-2 is a critical target for treatment of osteoclastogenesis enhanced in myeloma.

Teramachi J, Hiasa M, Oda A, Harada T, Nakamura S, Amachi R, Tenshin H, Iwasa M, Fujii S, Kagawa K, Miki H, Kurahashi K, Yoshida S, Endo I, Haneji T, Matsumoto T, Abe M.

Br J Haematol. 2018 Feb;180(4):581-585. doi: 10.1111/bjh.14388. Epub 2016 Oct 17. No abstract available.

PMID:
27748523
12.

Synergistic targeting of Sp1, a critical transcription factor for myeloma cell growth and survival, by panobinostat and proteasome inhibitors.

Bat-Erdene A, Miki H, Oda A, Nakamura S, Teramachi J, Amachi R, Tenshin H, Hiasa M, Iwasa M, Harada T, Fujii S, Sogabe K, Kagawa K, Yoshida S, Endo I, Aihara K, Abe M.

Oncotarget. 2016 Nov 29;7(48):79064-79075. doi: 10.18632/oncotarget.12594.

13.

A vicious cycle between acid sensing and survival signaling in myeloma cells: acid-induced epigenetic alteration.

Amachi R, Hiasa M, Teramachi J, Harada T, Oda A, Nakamura S, Hanson D, Watanabe K, Fujii S, Miki H, Kagawa K, Iwasa M, Endo I, Kondo T, Yoshida S, Aihara KI, Kurahashi K, Kuroda Y, Horikawa H, Tanaka E, Matsumoto T, Abe M.

Oncotarget. 2016 Oct 25;7(43):70447-70461. doi: 10.18632/oncotarget.11927.

14.

Urothelial ATP exocytosis: regulation of bladder compliance in the urine storage phase.

Nakagomi H, Yoshiyama M, Mochizuki T, Miyamoto T, Komatsu R, Imura Y, Morizawa Y, Hiasa M, Miyaji T, Kira S, Araki I, Fujishita K, Shibata K, Shigetomi E, Shinozaki Y, Ichikawa R, Uneyama H, Iwatsuki K, Nomura M, de Groat WC, Moriyama Y, Takeda M, Koizumi S.

Sci Rep. 2016 Jul 14;6:29761. doi: 10.1038/srep29761.

15.

Expression of Vesicular Nucleotide Transporter in the Mouse Retina.

Moriyama S, Hiasa M.

Biol Pharm Bull. 2016;39(4):564-9. doi: 10.1248/bpb.b15-00872.

16.

Involvement of multiple CCN family members in platelets that support regeneration of joint tissues.

Hara C, Kubota S, Nishida T, Hiasa M, Hattori T, Aoyama E, Moriyama Y, Kamioka H, Takigawa M.

Mod Rheumatol. 2016 Nov;26(6):940-949. doi: 10.3109/14397595.2016.1155255. Epub 2016 Apr 21.

PMID:
26915735
17.

Bidirectional Notch Signaling and Osteocyte-Derived Factors in the Bone Marrow Microenvironment Promote Tumor Cell Proliferation and Bone Destruction in Multiple Myeloma.

Delgado-Calle J, Anderson J, Cregor MD, Hiasa M, Chirgwin JM, Carlesso N, Yoneda T, Mohammad KS, Plotkin LI, Roodman GD, Bellido T.

Cancer Res. 2016 Mar 1;76(5):1089-100. doi: 10.1158/0008-5472.CAN-15-1703. Epub 2016 Feb 1.

18.

Structure, Function, and Drug Interactions of Neurotransmitter Transporters in the Postgenomic Era.

Omote H, Miyaji T, Hiasa M, Juge N, Moriyama Y.

Annu Rev Pharmacol Toxicol. 2016;56:385-402. doi: 10.1146/annurev-pharmtox-010814-124816. Epub 2015 Oct 22. Review.

PMID:
26514205
19.

Effective impairment of myeloma cells and their progenitors by blockade of monocarboxylate transportation.

Hanson DJ, Nakamura S, Amachi R, Hiasa M, Oda A, Tsuji D, Itoh K, Harada T, Horikawa K, Teramachi J, Miki H, Matsumoto T, Abe M.

Oncotarget. 2015 Oct 20;6(32):33568-86. doi: 10.18632/oncotarget.5598.

20.

Acidic microenvironment and bone pain in cancer-colonized bone.

Yoneda T, Hiasa M, Nagata Y, Okui T, White FA.

Bonekey Rep. 2015 May 6;4:690. doi: 10.1038/bonekey.2015.58. eCollection 2015. Review.

21.

Wide expression of type I Na+-phosphate cotransporter 3 (NPT3/SLC17A2), a membrane potential-driven organic anion transporter.

Togawa N, Juge N, Miyaji T, Hiasa M, Omote H, Moriyama Y.

Am J Physiol Cell Physiol. 2015 Jul 15;309(2):C71-80. doi: 10.1152/ajpcell.00048.2015. Epub 2015 May 13.

PMID:
25972451
22.

Contribution of acidic extracellular microenvironment of cancer-colonized bone to bone pain.

Yoneda T, Hiasa M, Nagata Y, Okui T, White F.

Biochim Biophys Acta. 2015 Oct;1848(10 Pt B):2677-84. doi: 10.1016/j.bbamem.2015.02.004. Epub 2015 Feb 14. Review.

23.

Identification of a mammalian vesicular polyamine transporter.

Hiasa M, Miyaji T, Haruna Y, Takeuchi T, Harada Y, Moriyama S, Yamamoto A, Omote H, Moriyama Y.

Sci Rep. 2014 Oct 30;4:6836. doi: 10.1038/srep06836.

24.

Impairment of vesicular ATP release affects glucose metabolism and increases insulin sensitivity.

Sakamoto S, Miyaji T, Hiasa M, Ichikawa R, Uematsu A, Iwatsuki K, Shibata A, Uneyama H, Takayanagi R, Yamamoto A, Omote H, Nomura M, Moriyama Y.

Sci Rep. 2014 Oct 21;4:6689. doi: 10.1038/srep06689.

25.
26.

Essential role of vesicular nucleotide transporter in vesicular storage and release of nucleotides in platelets.

Hiasa M, Togawa N, Miyaji T, Omote H, Yamamoto A, Moriyama Y.

Physiol Rep. 2014 Jun 6;2(6). pii: e12034. doi: 10.14814/phy2.12034. Print 2014 Jun 1.

27.

Pim-2 kinase is an important target of treatment for tumor progression and bone loss in myeloma.

Hiasa M, Teramachi J, Oda A, Amachi R, Harada T, Nakamura S, Miki H, Fujii S, Kagawa K, Watanabe K, Endo I, Kuroda Y, Yoneda T, Tsuji D, Nakao M, Tanaka E, Hamada K, Sano S, Itoh K, Matsumoto T, Abe M.

Leukemia. 2015 Jan;29(1):207-17. doi: 10.1038/leu.2014.147. Epub 2014 May 2.

PMID:
24787487
28.

Fabrications of zinc-releasing biocement combining zinc calcium phosphate to calcium phosphate cement.

Horiuchi S, Hiasa M, Yasue A, Sekine K, Hamada K, Asaoka K, Tanaka E.

J Mech Behav Biomed Mater. 2014 Jan;29:151-60. doi: 10.1016/j.jmbbm.2013.09.005. Epub 2013 Sep 14.

PMID:
24090874
29.
30.

Activating transcription factor 4, an ER stress mediator, is required for, but excessive ER stress suppresses osteoblastogenesis by bortezomib.

Nakamura S, Miki H, Kido S, Nakano A, Hiasa M, Oda A, Amou H, Watanabe K, Harada T, Fujii S, Takeuchi K, Kagawa K, Ozaki S, Matsumoto T, Abe M.

Int J Hematol. 2013 Jul;98(1):66-73. doi: 10.1007/s12185-013-1367-z. Epub 2013 May 25.

PMID:
23708974
31.

Vesicular nucleotide transporter regulates the nucleotide content in airway epithelial mucin granules.

Sesma JI, Kreda SM, Okada SF, van Heusden C, Moussa L, Jones LC, O'Neal WK, Togawa N, Hiasa M, Moriyama Y, Lazarowski ER.

Am J Physiol Cell Physiol. 2013 May 15;304(10):C976-84. doi: 10.1152/ajpcell.00371.2012. Epub 2013 Mar 6. Erratum in: Am J Physiol Cell Physiol. 2014 Feb 15;306(4):C415.

32.

Inhibition of MAO-A and stimulation of behavioural activities in mice by the inactive prodrug form of the anti-influenza agent oseltamivir.

Hiasa M, Isoda Y, Kishimoto Y, Saitoh K, Kimura Y, Kanai M, Shibasaki M, Hatakeyama D, Kirino Y, Kuzuhara T.

Br J Pharmacol. 2013 May;169(1):115-29. doi: 10.1111/bph.12102.

33.

Small molecule antibody targeting HLA class I inhibits myeloma cancer stem cells by repressing pluripotency-associated transcription factors.

Ikegame A, Ozaki S, Tsuji D, Harada T, Fujii S, Nakamura S, Miki H, Nakano A, Kagawa K, Takeuchi K, Abe M, Watanabe K, Hiasa M, Kimura N, Kikuchi Y, Sakamoto A, Habu K, Endo M, Itoh K, Yamada-Okabe H, Matsumoto T.

Leukemia. 2012 Sep;26(9):2124-34. doi: 10.1038/leu.2012.78. Epub 2012 Mar 20.

PMID:
22430632
34.

KRN5500, a spicamycin derivative, exerts anti-myeloma effects through impairing both myeloma cells and osteoclasts.

Miki H, Ozaki S, Nakamura S, Oda A, Amou H, Ikegame A, Watanabe K, Hiasa M, Cui Q, Harada T, Fujii S, Nakano A, Kagawa K, Takeuchi K, Yata K, Sakai A, Abe M, Matsumoto T.

Br J Haematol. 2011 Nov;155(3):328-39. doi: 10.1111/j.1365-2141.2011.08844.x. Epub 2011 Sep 9.

PMID:
21902681
35.

Functional and anatomical identification of a vesicular transporter mediating neuronal ATP release.

Larsson M, Sawada K, Morland C, Hiasa M, Ormel L, Moriyama Y, Gundersen V.

Cereb Cortex. 2012 May;22(5):1203-14. doi: 10.1093/cercor/bhr203. Epub 2011 Aug 1.

PMID:
21810784
36.

Reinforcement of bond strength of self-etching orthodontic adhesive.

Horiuchi S, Kuroda S, Hiasa M, Suge T, Saku S, Hamada K, Matsuo T, Asaoka K, Tanaka E.

Angle Orthod. 2012 Jan;82(1):30-5. doi: 10.2319/012011-39.1. Epub 2011 Jul 13.

PMID:
21751834
37.

Targeting myeloma-osteoclast interaction with Vγ9Vδ2 T cells.

Cui Q, Shibata H, Oda A, Amou H, Nakano A, Yata K, Hiasa M, Watanabe K, Nakamura S, Miki H, Harada T, Fujii S, Kagawa K, Takeuchi K, Ozaki S, Matsumoto T, Abe M.

Int J Hematol. 2011 Jul;94(1):63-70. doi: 10.1007/s12185-011-0885-9. Epub 2011 Jun 23.

PMID:
21698356
38.

Delayed treatment with vitamin C and N-acetyl-L-cysteine protects Schwann cells without compromising the anti-myeloma activity of bortezomib.

Nakano A, Abe M, Oda A, Amou H, Hiasa M, Nakamura S, Miki H, Harada T, Fujii S, Kagawa K, Takeuchi K, Watanabe T, Ozaki S, Matsumoto T.

Int J Hematol. 2011 Jun;93(6):727-735. doi: 10.1007/s12185-011-0850-7. Epub 2011 Apr 28.

PMID:
21526377
39.

The serine/threonine kinase Pim-2 is a novel anti-apoptotic mediator in myeloma cells.

Asano J, Nakano A, Oda A, Amou H, Hiasa M, Takeuchi K, Miki H, Nakamura S, Harada T, Fujii S, Kagawa K, Endo I, Yata K, Sakai A, Ozaki S, Matsumoto T, Abe M.

Leukemia. 2011 Jul;25(7):1182-8. doi: 10.1038/leu.2011.60. Epub 2011 Apr 8.

PMID:
21475253
40.

Characterization of the human MATE2 proton-coupled polyspecific organic cation exporter.

Komatsu T, Hiasa M, Miyaji T, Kanamoto T, Matsumoto T, Otsuka M, Moriyama Y, Omote H.

Int J Biochem Cell Biol. 2011 Jun;43(6):913-8. doi: 10.1016/j.biocel.2011.03.005. Epub 2011 Mar 17.

PMID:
21419862
41.

Type 1 sodium-dependent phosphate transporter (SLC17A1 Protein) is a Cl(-)-dependent urate exporter.

Iharada M, Miyaji T, Fujimoto T, Hiasa M, Anzai N, Omote H, Moriyama Y.

J Biol Chem. 2010 Aug 20;285(34):26107-13. doi: 10.1074/jbc.M110.122721. Epub 2010 Jun 21.

42.

Tgf-Beta inhibition restores terminal osteoblast differentiation to suppress myeloma growth.

Takeuchi K, Abe M, Hiasa M, Oda A, Amou H, Kido S, Harada T, Tanaka O, Miki H, Nakamura S, Nakano A, Kagawa K, Yata K, Ozaki S, Matsumoto T.

PLoS One. 2010 Mar 25;5(3):e9870. doi: 10.1371/journal.pone.0009870.

43.

Vesicular inhibitory amino acid transporter is a Cl-/gamma-aminobutyrate Co-transporter.

Juge N, Muroyama A, Hiasa M, Omote H, Moriyama Y.

J Biol Chem. 2009 Dec 11;284(50):35073-8. doi: 10.1074/jbc.M109.062414. Epub 2009 Oct 20.

44.

GM-CSF and IL-4 induce dendritic cell differentiation and disrupt osteoclastogenesis through M-CSF receptor shedding by up-regulation of TNF-alpha converting enzyme (TACE).

Hiasa M, Abe M, Nakano A, Oda A, Amou H, Kido S, Takeuchi K, Kagawa K, Yata K, Hashimoto T, Ozaki S, Asaoka K, Tanaka E, Moriyama K, Matsumoto T.

Blood. 2009 Nov 12;114(20):4517-26. doi: 10.1182/blood-2009-04-215020. Epub 2009 Sep 17.

45.

Identification of the vesicular nucleotide transporter (VNUT) in taste cells.

Iwatsuki K, Ichikawa R, Hiasa M, Moriyama Y, Torii K, Uneyama H.

Biochem Biophys Res Commun. 2009 Oct 9;388(1):1-5. doi: 10.1016/j.bbrc.2009.07.069. Epub 2009 Jul 18.

PMID:
19619506
46.

Valproic acid exerts anti-tumor as well as anti-angiogenic effects on myeloma.

Kitazoe KI, Abe M, Hiasa M, Oda A, Amou H, Harada T, Nakano A, Takeuchi K, Hashimoto T, Ozaki S, Matsumoto T.

Int J Hematol. 2009 Jan;89(1):45-57. doi: 10.1007/s12185-008-0226-9. Epub 2008 Dec 18.

PMID:
19093163
47.

Identification of a vesicular aspartate transporter.

Miyaji T, Echigo N, Hiasa M, Senoh S, Omote H, Moriyama Y.

Proc Natl Acad Sci U S A. 2008 Aug 19;105(33):11720-4. doi: 10.1073/pnas.0804015105. Epub 2008 Aug 11.

48.

Multidrug and toxic compound extrusion (MATE)-type proteins as anchor transporters for the excretion of metabolic waste products and xenobiotics.

Moriyama Y, Hiasa M, Matsumoto T, Omote H.

Xenobiotica. 2008 Jul;38(7-8):1107-18. doi: 10.1080/00498250701883753 . Review.

PMID:
18668441
49.

Expression and function of TETRAN, a new type of membrane transporter.

Ushijima H, Hiasa M, Namba T, Hwang HJ, Hoshino T, Mima S, Tsuchiya T, Moriyama Y, Mizushima T.

Biochem Biophys Res Commun. 2008 Sep 19;374(2):325-30. doi: 10.1016/j.bbrc.2008.07.034. Epub 2008 Jul 16.

PMID:
18638446
50.

[Identification, structure and function of a drug transporter at the final step of extrusion].

Hiasa M, Omote H, Moriyama Y.

Tanpakushitsu Kakusan Koso. 2008 Jan;53(1):52-8. Review. Japanese. No abstract available.

PMID:
18186303

Supplemental Content

Support Center